News
ILMN
214.26
-4.75%
-10.68
Earnings week ahead: PepsiCo, Disney, BP, Chipotle and more
Seeking Alpha · 18h ago
Peltz's Trian seeks to rally Disney shareholders against board director Froman
Reuters · 2d ago
Magistrate Judge Issued Favorable Recommendation Regarding Guardant Health's Motion To Dismiss Lawsuit Brought By Illumina
Benzinga · 2d ago
RBC Capital Sticks to Their Buy Rating for Illumina (ILMN)
TipRanks · 2d ago
Ensemble Capital Fourth Quarter 2022 Investor Letter
Seeking Alpha · 3d ago
Joydeep Goswami is the new finance chief of Illumina
Seeking Alpha · 3d ago
Illumina Makes Its Interim CFO Permanent
The Wall Street Journal · 3d ago
Illumina Names Joydeep Goswami Chief Financial Officer
Illumina Names Joydeep Goswami Chief Financial Officer
MT Newswires · 3d ago
GE HealthCare Technologies: Still Significantly Undervalued
Seeking Alpha · 4d ago
Bionano's Balance Sheet Challenges: History Repeating Itself
Seeking Alpha · 4d ago
Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update
Seeking Alpha · 5d ago
7 Analysts Have This to Say About Illumina
Benzinga · 01/25 15:01
Illumina downgraded to hold at Argus on poor near-term outlook
Seeking Alpha · 01/25 14:12
Argus Research Downgrades Illumina to Hold
Benzinga · 01/25 13:15
Argus Research Downgrades Illumina to Hold Rating From Buy
Argus Research Downgrades Illumina to Hold Rating From Buy
MT Newswires · 01/25 10:03
Bruker Corp.: My Top Ranked Holding In Laboratory Analytical Instruments
Seeking Alpha · 01/19 08:50
NIH outlays fall, US govt healthcare grants grow but Biopharma financings decline Y/Y
Seeking Alpha · 01/18 17:03
Canaccord Genuity Maintains Buy on Illumina, Lowers Price Target to $300
Benzinga · 01/17 13:06
Canaccord Genuity Adjusts Price Target on Illumina to $300 From $330, Maintains Buy Rating
Canaccord Genuity Adjusts Price Target on Illumina to $300 From $330, Maintains Buy Rating
MT Newswires · 01/17 08:51
Why Chip Maker Nvidia Was at a Healthcare Conference
Barron's · 01/14 19:01
More
Webull provides a variety of real-time ILMN stock news. You can receive the latest news about Illumina Inc through multiple platforms. This information may help you make smarter investment decisions.
About ILMN
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.